NCT03243734Completed
trūFreeze® Palliative Esophageal Cancer
A Prospective Single Arm Multicenter Study Evaluating the Effects of Spray Cryotherapy in Patients With Persistent Local Esophageal Cancer
Source: ClinicalTrials.gov · Last updated 8 May 2024
Brief summary (registry, in English)
Prospective, open label, non-controlled single arm, multi-center study The primary objective is to study the effects of the trūFreeze® Spray Cryotherapy System in a population of subjects who have been diagnosed with persistent local esophageal cancer and who are not surgical candidates or have completed or declined systemic therapy.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 49 (actual)
- First submitted
- 3 Aug 2017
- Start date
- 6 Nov 2017
- Primary completion date
- 13 Jul 2022
- Lead sponsor
- US Endoscopy Group Inc.
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT03243734
What you commit to
- Study type: Interventional
- Participants enrolled: 49
- From 6 Nov 2017 to the primary completion date, 13 Jul 2022
- 10 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subject has received radiation within the past 6 weeks
- Subject has received chemotherapy within the past 2 weeks Subject has received immunotherapy within 30 days
- Subject has participated in another clinical study for systemic therapy within 6 weeks of baseline.
- Subject has had previous Spray Cryotherapy for esophageal cancer.
Other
- Subject is pregnant, nursing, or planning to get pregnant during study duration.
- Subjects with an esophageal stent in situ at the time of study enrollment
- Subject, as deemed by treating investigator has contraindication to endoscopy or Spray Cryotherapy Procedure.
Who the study is looking for
- Males and females of 18 to 89 years of age.
- Subject is able to read, understand, and sign a written Informed Consent to participate in the study.
- Subject has persistent esophageal cancer with local luminal involvement and who is not a surgical candidate or has completed or declined systemic therapy.
- Subject is able to tolerate endoscopy
Age in the registry: 18 years to 89 years · Sex: All · Does not accept healthy volunteers
Sites (10)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Emory University Coordinator of this site? Confirm its status | Atlanta | United States | Unknown status |
| University of North Carolina at Chapel Hill Coordinator of this site? Confirm its status | Chapel Hill | United States | Unknown status |
| Parkview Comprehensive Cancer Center Coordinator of this site? Confirm its status | Fort Wayne | United States | Unknown status |
| Cancer Treatment Centers of America Western Regional Medical Center Coordinator of this site? Confirm its status | Goodyear | United States | Unknown status |
| Spectrum Health Coordinator of this site? Confirm its status | Grand Rapids | United States | Unknown status |
| Dartmouth-Hotchcock Medical Center Coordinator of this site? Confirm its status | Lebanon | United States | Unknown status |
| North Shore-Long Island Jewish Medical Center Coordinator of this site? Confirm its status | Manhasset | United States | Unknown status |
| University of California at Irvine Coordinator of this site? Confirm its status | Orange | United States | Unknown status |
| Virginia Commonwealth University Coordinator of this site? Confirm its status | Richmond | United States | Unknown status |
| University of Rochester Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.